Von Hippel-Lindau gene product directs cytokinesis: a new tumor suppressor function
暂无分享,去创建一个
D. Mukhopadhyay | F. Couch | S. Sinha | Seethalakshmi Iyer | S. Dutta | S. Karumanchi | Keun-Il Kim | Eun Ju Hwang | Gourish Mondal | D. Han
[1] D. Mukhopadhyay,et al. Von Hippel-Lindau Gene Product Modulates TIS11B Expression in Renal Cell Carcinoma , 2009, The Journal of Biological Chemistry.
[2] D. Mukhopadhyay,et al. Dopamine regulates phosphorylation of VEGF receptor 2 by engaging Src-homology-2-domain-containing protein tyrosine phosphatase 2 , 2009, Journal of Cell Science.
[3] H. Moch,et al. VHL loss causes spindle misorientation and chromosome instability , 2009, Nature Cell Biology.
[4] V. Pankratz,et al. Microcephalin regulates BRCA2 and Rad51-associated DNA double-strand break repair. , 2009, Cancer research.
[5] D. Mukhopadhyay,et al. VEGF neutralizing antibody increases the therapeutic efficacy of vinorelbine for renal cell carcinoma , 2008, Journal of cellular and molecular medicine.
[6] C. Croce,et al. MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis , 2008, Proceedings of the National Academy of Sciences.
[7] S. Gygi,et al. Human ESCRT and ALIX proteins interact with proteins of the midbody and function in cytokinesis , 2007, The EMBO journal.
[8] R. Green,et al. APC mutations lead to cytokinetic failures in vitro and tetraploid genotypes in Min mice , 2007, The Journal of cell biology.
[9] L. Truong,et al. Expression of GLUT1 in primary renal tumors: morphologic and biologic implications. , 2007, American journal of clinical pathology.
[10] J. Martin-Serrano,et al. Parallels Between Cytokinesis and Retroviral Budding: A Role for the ESCRT Machinery , 2007, Science.
[11] Kentaro Takahashi,et al. Von Hippel-Lindau Disease , 2024 .
[12] E. Cho,et al. p53 stabilization and transactivation by a von Hippel-Lindau protein. , 2006, Molecular cell.
[13] A. Terzic,et al. Early aging–associated phenotypes in Bub3/Rae1 haploinsufficient mice , 2006, The Journal of cell biology.
[14] David Pellman,et al. Cytokinesis failure generating tetraploids promotes tumorigenesis in p53-null cells , 2005, Nature.
[15] K. Khanna,et al. Cdk1/Erk2- and Plk1-dependent phosphorylation of a centrosome protein, Cep55, is required for its recruitment to midbody and cytokinesis. , 2005, Developmental cell.
[16] W. Kaelin,et al. Role of VHL gene mutation in human cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] E. Voest,et al. The von Hippel-Lindau tumor suppressor protein influences microtubule dynamics at the cell periphery. , 2004, Experimental cell research.
[18] A. Venkitaraman,et al. Abnormal Cytokinesis in Cells Deficient in the Breast Cancer Susceptibility Protein BRCA2 , 2004, Science.
[19] M. Guo,et al. Expression of fibronectin and HIF-1alpha in renal cell carcinomas: relationship to von Hippel-Lindau gene inactivation. , 2004, Cancer genetics and cytogenetics.
[20] Hongmei Wang,et al. Tumor Suppressor von Hippel-Lindau (VHL) Stabilization of Jade-1 Protein Occurs through Plant Homeodomains and Is VHL Mutation Dependent , 2004, Cancer Research.
[21] W. Sundquist,et al. The Protein Network of HIV Budding , 2003, Cell.
[22] A. Calistri,et al. AIP1/ALIX Is a Binding Partner for HIV-1 p6 and EIAV p9 Functioning in Virus Budding , 2003, Cell.
[23] T. Weimbs,et al. Syntaxin 2 and endobrevin are required for the terminal step of cytokinesis in mammalian cells. , 2003, Developmental cell.
[24] I. Kuzmin,et al. The von Hippel-Lindau Tumor Suppressor Stabilizes Novel Plant Homeodomain Protein Jade-1* , 2002, The Journal of Biological Chemistry.
[25] Min Wang,et al. The Small Ubiquitin-like Modifier-1 (SUMO-1) Consensus Sequence Mediates Ubc9 Binding and Is Essential for SUMO-1 Modification* , 2001, The Journal of Biological Chemistry.
[26] R. Hay,et al. SUMO-1 Conjugation in Vivo Requires Both a Consensus Modification Motif and Nuclear Targeting* , 2001, The Journal of Biological Chemistry.
[27] S. Sen,et al. Aneuploidy and cancer , 2000, Current opinion in oncology.
[28] C. Wykoff,et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis , 1999, Nature.
[29] W. Kaelin,et al. Structure of the VHL-ElonginC-ElonginB complex: implications for VHL tumor suppressor function. , 1999, Science.
[30] R. Burk,et al. A second major native von Hippel-Lindau gene product, initiated from an internal translation start site, functions as a tumor suppressor. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[31] D. Louis,et al. The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix. , 1998, Molecular cell.
[32] M. Goldberg,et al. Hypoxia-inducible Protein Binding to Vascular Endothelial Growth Factor mRNA and Its Modulation by the von Hippel-Lindau Protein* , 1996, The Journal of Biological Chemistry.
[33] R. Klausner,et al. Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[34] W. Kaelin,et al. Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[35] G. Martiny-Baron,et al. Reversion of deregulated expression of vascular endothelial growth factor in human renal carcinoma cells by von Hippel-Lindau tumor suppressor protein. , 1996, Cancer research.
[36] A. Kibel,et al. Tumour suppression by the human von Hippel-Lindau gene product , 1995, Nature Medicine.
[37] M. Lerman,et al. Identification of intragenic mutations in the von Hippel-Lindau disease tumour suppressor gene and correlation with disease phenotype. , 1994, Human molecular genetics.
[38] J. Brooks,et al. Mutations of the VHL tumour suppressor gene in renal carcinoma , 1994, Nature Genetics.
[39] M. Lerman,et al. Detailed mapping of germline deletions of the von Hippel-Lindau disease tumour suppressor gene. , 1994, Human molecular genetics.
[40] W. Linehan,et al. Mapping the Von Hippel-Lindau disease tumour suppressor gene: identification of germline deletions by pulsed field gel electrophoresis. , 1993, Human molecular genetics.
[41] E. Voest,et al. Tumor suppressors APC and VHL: gatekeepers of the intestine and kidney. , 2005, Progress in molecular and subcellular biology.
[42] F. Speleman,et al. Rapid detection of VHL exon deletions using real-time quantitative PCR , 2005, Laboratory Investigation.
[43] W. Krek,et al. Regulation of microtubule stability by the von Hippel-Lindau tumour suppressor protein pVHL , 2003, Nature Cell Biology.
[44] W. Linehan,et al. Improved detection of germline mutations in the von Hippel‐Lindau disease tumor suppressor gene , 1998, Human mutation.
[45] W. Linehan,et al. Germline mutations in the Von Hippel‐Lindau disease (VHL) gene in families from North America, Europe, and Japan , 1996, Human mutation.
[46] in the protein , 2022 .